Clinical trial Recruiting at 3 sites Phase 3 Interventional Ages 18 and up

Early treatment with noradrenaline for shock in emergency departments

Official title: Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled Trial

Run by Odense University Hospital · NCT05931601 · Data updated 2026-11-12

This study tests if giving noradrenaline right away helps people in shock feel better and recover faster than just using standard fluids.

More Shock trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment320 (estimated)
SponsorOdense University Hospital
Academic / other
Locations8 sites (Copenhagen and 7 other locations)
StatusRecruiting
StartedDecember 8, 2023
Main results expectedDecember 31, 2026
Study endsJanuary 31, 2027
Registry record updatedJuly 1, 2025
Trial IDNCT05931601 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older presenting with signs of hypotension or shock who have received at least 500ml of intravenous fluid within the first 4 hours of emergency department arrival.

Probably not a fit

Patients with a Clinical Frailty Score of 5 or higher who are not suitable for ICU admission may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of early initiated peripheral infusion of noradrenaline compared to standard fluid therapy in patients experiencing hypotension and shock in Danish Emergency Departments. It is a pragmatic, multi-center, superiority, randomized trial that will assess outcomes such as time to shock control, ICU admission rates, and mortality. Participants will receive either noradrenaline or usual treatment urgently upon presentation, and their health data will be collected for analysis. Follow-up will occur one year after treatment to gather additional patient-reported outcomes.

Why it matters

Potential benefit: If successful, this approach could lead to improved management of hypotensive patients, potentially reducing mortality and ICU admissions.

How similar studies have gone: Other studies have shown promising results with early vasopressor therapy in similar contexts, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* At least 18 years of age
* Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as:

  1. SBP \< 100mmHg or MAP \< 65 mmHg combined with lactate \> 2.0 mmol/L,
  2. Physician defined blood pressure for the individual patient combined with a lactate \> 2.0 mmol/L
  3. Either SBP \< 100mmHg or MAP \< 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician.
* Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival.
* Clinical Frailty Score (CFS) of ≤4. If CFS is ≥5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion.

Exclusion Criteria:

* Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician.
* Fertile women (\<60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding.
* Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant.
* Known allergy to noradrenaline.

Where it's running

  • Bispebjerg Hospital
    Copenhagen, Denmark
    Recruiting
  • Zealand University Hospital
    Køge, Denmark
    Recruiting
  • Odense University Hospital
    Odense, Denmark
    Recruiting
  • Esbjerg Hospital
    Esbjerg, Denmark
    Terminated
  • Gødstrup Regional Hospital
    Herning, Denmark
    Not yet recruiting
  • Department of Emergency Medicine
    Helsingborg, Sweden
    Not yet recruiting
Show 2 more locations
  • Department of Emergency Medicine
    Linköping, Sweden
    Not yet recruiting
  • Department of Emergency Medicine
    Ystad, Sweden
    Not yet recruiting

Study contacts

  • Principal investigator: Lasse P Bentsen, MD — Department of Emergency Medicine, Odense University Hospital
  • Study coordinator: Lasse P Bentsen, MD
  • Email: lasse.paludan.bentsen@rsyd.dk
  • Phone: +4520496950

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.